#United States #NRx Pharmaceuticals #La Jolla #Hope Therapeutics #Kadima Neuropsychiatry

Hope Therapeutics Expands with Kadima Acquisition

In a significant step towards enhancing mental health treatment, Hope Therapeutics, Inc. and its parent company, NRx Pharmaceuticals, Inc., have announced their first acquisition targeting the establishment of an international network of interventional psychiatry clinics. The Kadima Neuropsychiatry Institute, located in La Jolla, California, is set to serve as a flagship clinic, dedicated to treating conditions like depression and PTSD.

A New Dawn for Interventional Psychiatry

Kadima, renowned for its advanced interventional approaches, was among the pioneering clinics to utilize Ketamine Therapy at a large scale for addressing Central Nervous System (CNS) disorders. Their extensive range of therapies also includes Spravato® (nasal esketamine) and Transcranial Magnetic Stimulation (TMS), reinforcing their commitment to providing innovative treatment options for serious psychiatric conditions.

Dr. David Feifel, the founder of Kadima, will join Hope Therapeutics as their Chief Medical Innovation Officer. With a rich history spanning over 30 years in the field of psychiatry, Dr. Feifel is recognized for his contributions to interventional treatments. He has played a pivotal role in clinical research, particularly in the realm of psychedelic therapies, making Kadima a leading investigative site in numerous pivotal clinical trials.

Bridging Research and Treatment

Kadima’s status as a top research facility ensures that it remains at the forefront of CNS innovations. The clinic maintains collaborations with the U.S. Department of Veterans Affairs, providing essential treatments to veterans and active-duty military members, thereby addressing the critical need for mental health support in these communities.

Hope Therapeutics aims to replicate Kadima's success globally, focusing on adopting and enhancing innovative approaches that tackle the challenges posed by mood disorders. As Dr. Feifel stated, his mission is to expand the successes of Kadima on an international scale, with a goal to transform suicidal depression and PTSD into treatable conditions. He believes that patients and their families should expect to reclaim empowered and productive lives.

The Future of Mental Health Care

The integration of Kadima's practices into the Hope Therapeutics network signals a move towards a more cohesive, multi-modal approach in treating psychiatric disorders. Dr. Feifel’s involvement is expected to lead to new developments that prioritize interventional techniques alongside traditional treatments. Dr. Jonathan Javitt, a co-CEO at Hope, highlighted the significance of Dr. Feifel’s expertise, emphasizing that together they can expand innovative solutions to reach a greater population.

The acquisition is not just a business expansion; it underscores a commitment to advancing mental health care and improving patient outcomes. With rising mental health challenges affecting millions globally, the team at Hope Therapeutics is poised to lead a transformative change in how psychiatric conditions are treated. They aspire to harness their combined experience and knowledge to carve a future where effective, integrated treatments are the norm for those affected by mental illness.

As Hope Therapeutics moves forward with plans for the acquisition, they anticipate positive impacts on revenue and EBITDA for NRx Pharmaceuticals, aligning financial success with their broader mission to improve mental health outcomes worldwide.

This initiative represents not just a strategic business choice, but a compassionate response to the escalating mental health crisis affecting society today. Through this acquisition, Hope Therapeutics is not only expanding its footprint but also reaffirming its dedication to pioneering comprehensive and effective mental health care solutions for those in dire need.